Skip to main content
Top
Published in: Critical Care 2/2003

01-04-2004 | Commentary

Coagulation in sepsis: all bugs bite equally

Authors: Marcel Levi, Tom van der Poll

Published in: Critical Care | Issue 2/2003

Login to get access

Abstract

Sepsis almost invariably leads to hemostatic abnormalities, ranging from insignificant laboratory changes to severe disseminated intravascular coagulation. There is compelling evidence from clinical and experimental studies that disseminated intravascular coagulation is involved in the pathogenesis of microvascular dysfunction and contributes to organ failure. Data from the PROWESS phase III clinical trial of recombinant activated protein C in patients with severe sepsis confirm this notion and demonstrate that the vast majority of patients with severe sepsis have increased markers for systemic coagulation activation, decreased physiological anticoagulant proteins and depressed fibrinolysis. There is no correlation between the type of microorganism that has caused the infection and the presence or severity of the coagulation disorder.
Literature
1.
go back to reference Kinasewitz GT, Yan SB, Basson B, Comp P, Russell JA, Cariou A, Um SL, Utterback B, Laterre P-F, Dhainaut J-F, for the PROWESS Sepsis Study Group: Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]. Crit Care 2004, 8: R82-R90. 10.1186/cc2459PubMedCentralCrossRefPubMed Kinasewitz GT, Yan SB, Basson B, Comp P, Russell JA, Cariou A, Um SL, Utterback B, Laterre P-F, Dhainaut J-F, for the PROWESS Sepsis Study Group: Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]. Crit Care 2004, 8: R82-R90. 10.1186/cc2459PubMedCentralCrossRefPubMed
2.
go back to reference Levi M, ten Cate H: Disseminated intravascular coagulation. N Engl J Med 1999, 341: 586-592. 10.1056/NEJM199908193410807CrossRefPubMed Levi M, ten Cate H: Disseminated intravascular coagulation. N Engl J Med 1999, 341: 586-592. 10.1056/NEJM199908193410807CrossRefPubMed
3.
go back to reference Levi M, Keller TT, van Gorp E, ten Cate H: Infection and inflammation and the coagulation system. Cardiovasc Res 2003, 60: 26-39. 10.1016/S0008-6363(02)00857-XCrossRefPubMed Levi M, Keller TT, van Gorp E, ten Cate H: Infection and inflammation and the coagulation system. Cardiovasc Res 2003, 60: 26-39. 10.1016/S0008-6363(02)00857-XCrossRefPubMed
4.
go back to reference Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr, Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344: 699-709. 10.1056/NEJM200103083441001CrossRefPubMed Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr, Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344: 699-709. 10.1056/NEJM200103083441001CrossRefPubMed
5.
go back to reference Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM, KyberSept Trial Study Group: Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001, 286: 1869-1878. 10.1001/jama.286.15.1869CrossRefPubMed Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM, KyberSept Trial Study Group: Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001, 286: 1869-1878. 10.1001/jama.286.15.1869CrossRefPubMed
6.
go back to reference Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, Light B, Spapen H, Stone J, Seibert A, Peckelsen C, De Deyne C, Postier R, Pettila V, Artigas A, Percell SR, Shu V, Zwingelstein C, Tobias J, Poole L, Stolzenbach JC, Creasey AA, OPTIMIST Trial Study Group: Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003, 290: 238-247. 10.1001/jama.290.2.238CrossRefPubMed Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, Light B, Spapen H, Stone J, Seibert A, Peckelsen C, De Deyne C, Postier R, Pettila V, Artigas A, Percell SR, Shu V, Zwingelstein C, Tobias J, Poole L, Stolzenbach JC, Creasey AA, OPTIMIST Trial Study Group: Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003, 290: 238-247. 10.1001/jama.290.2.238CrossRefPubMed
7.
go back to reference Levi M, de Jonge E, van der Poll T: Recombinant human activated protein C (Xigris). Int J Clin Pract 2002, 56: 542-545.PubMed Levi M, de Jonge E, van der Poll T: Recombinant human activated protein C (Xigris). Int J Clin Pract 2002, 56: 542-545.PubMed
8.
go back to reference Bernard GR, Ely EW, Wright TJ, Fraiz J, Stasek JE Jr, Russell JA, Mayers I, Rosenfeld BA, Morris PE, Yan SB, Helterbrand JD: Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 2001, 29: 2051-2059. 10.1097/00003246-200111000-00003CrossRefPubMed Bernard GR, Ely EW, Wright TJ, Fraiz J, Stasek JE Jr, Russell JA, Mayers I, Rosenfeld BA, Morris PE, Yan SB, Helterbrand JD: Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 2001, 29: 2051-2059. 10.1097/00003246-200111000-00003CrossRefPubMed
9.
go back to reference Dhainaut JF, Yan SB, Joyce DE, Pettila V, Basson BR, Brandt JT, Sundin D, Levi M: Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2004, in press. Dhainaut JF, Yan SB, Joyce DE, Pettila V, Basson BR, Brandt JT, Sundin D, Levi M: Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2004, in press.
10.
go back to reference Bone RC: Gram-positive organisms and sepsis. Arch Intern Med 1994, 154: 26-34. 10.1001/archinte.154.1.26CrossRefPubMed Bone RC: Gram-positive organisms and sepsis. Arch Intern Med 1994, 154: 26-34. 10.1001/archinte.154.1.26CrossRefPubMed
11.
go back to reference Mohanty D, Ghosh K, Nandwani SK, Shetty S, Phillips C, Rizvi S, Parmar BD: Fibrinolysis, inhibitors of blood coagulation, and monocyte derived coagulant activity in acute malaria. Am J Hematol 1997, 54: 23-29. 10.1002/(SICI)1096-8652(199701)54:1<23::AID-AJH4>3.3.CO;2-ECrossRefPubMed Mohanty D, Ghosh K, Nandwani SK, Shetty S, Phillips C, Rizvi S, Parmar BD: Fibrinolysis, inhibitors of blood coagulation, and monocyte derived coagulant activity in acute malaria. Am J Hematol 1997, 54: 23-29. 10.1002/(SICI)1096-8652(199701)54:1<23::AID-AJH4>3.3.CO;2-ECrossRefPubMed
12.
go back to reference Suharti C, van Gorp EC, Setiati TE, Dolmans WM, Djokomoeljanto RJ, Hack CE, ten CH, van der Meer JW: The role of cytokines in activation of coagulation and fibrinolysis in dengue shock syndrome. Thromb Haemost 2002, 87: 42-46.PubMed Suharti C, van Gorp EC, Setiati TE, Dolmans WM, Djokomoeljanto RJ, Hack CE, ten CH, van der Meer JW: The role of cytokines in activation of coagulation and fibrinolysis in dengue shock syndrome. Thromb Haemost 2002, 87: 42-46.PubMed
13.
go back to reference Sriskandan S, Kemball-Cook G, Moyes D, Canvin J, Tuddenham E, Cohen J: Contact activation in shock caused by invasive group A Streptococcus pyogenes. Crit Care Med 2000, 28: 3684-3691.CrossRefPubMed Sriskandan S, Kemball-Cook G, Moyes D, Canvin J, Tuddenham E, Cohen J: Contact activation in shock caused by invasive group A Streptococcus pyogenes. Crit Care Med 2000, 28: 3684-3691.CrossRefPubMed
14.
go back to reference Netea MG, Kullberg BJ, Joosten LA, Sprong T, Verschueren I, Boerman OC, Amiot F, van den Berg WB, Van der Meer JW: Lethal Escherichia coli and Salmonella typhimurium endotoxemia is mediated through different pathways. Eur J Immunol 2001, 31: 2529-2538. 10.1002/1521-4141(200109)31:9<2529::AID-IMMU2529>3.3.CO;2-2CrossRefPubMed Netea MG, Kullberg BJ, Joosten LA, Sprong T, Verschueren I, Boerman OC, Amiot F, van den Berg WB, Van der Meer JW: Lethal Escherichia coli and Salmonella typhimurium endotoxemia is mediated through different pathways. Eur J Immunol 2001, 31: 2529-2538. 10.1002/1521-4141(200109)31:9<2529::AID-IMMU2529>3.3.CO;2-2CrossRefPubMed
15.
go back to reference Opal SM, Garber GE, LaRosa SP, Maki DG, Freebairn RC, Kinasewitz GT, Dhainaut JF, Yan SB, Williams MD, Graham DE, Nelson DR, Levy H, Bernard GR: Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated). Clin Infect Dis 2003, 37: 50-58. 10.1086/375593CrossRefPubMed Opal SM, Garber GE, LaRosa SP, Maki DG, Freebairn RC, Kinasewitz GT, Dhainaut JF, Yan SB, Williams MD, Graham DE, Nelson DR, Levy H, Bernard GR: Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated). Clin Infect Dis 2003, 37: 50-58. 10.1086/375593CrossRefPubMed
Metadata
Title
Coagulation in sepsis: all bugs bite equally
Authors
Marcel Levi
Tom van der Poll
Publication date
01-04-2004
Publisher
BioMed Central
Published in
Critical Care / Issue 2/2003
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc2816

Other articles of this Issue 2/2003

Critical Care 2/2003 Go to the issue